Hester Biosciences Limited carries a current dividend yield hovering around 0.46 percent, reflecting its historical pattern of paying regular annual dividends. Because the company channels the majority of its earnings back into expanding its biological manufacturing infrastructure, international facilities in Africa and Nepal, and specialized vaccine research, dividend yields remain relatively low in favor of long-term capital appreciation.